According to GuruFocus Insider Data, the largest CFO buys during the past week were Information Services Group Inc (III, Financial), Magnum Hunter Resources Inc. (MHR, Financial), Columbia Laboratories Inc. (CBRX, Financial), NewBridge Bancorp (NBBC, Financial), Oculus Innovative Sciences Inc. (OCLS, Financial), Synovus Financial Corp. (SNV, Financial), and QLT Inc. (QLTI, Financial).
Information Services Group Inc (III): Executive VP and CFO David E. Berger Bought 125,000 Shares
Executive VP and CFO of Information Services Group Inc (III) David E. Berger bought 125,000 shares on 11/12/2009 at an average price of $3.17. INFORMATION SERVICES GROUP, INC. was founded to build an industry-leading, high-growth, information-based services company by acquiring and growing businesses in advisory, data, business and media information services. ISG's first acquisition - TPI, the world's leading data and advisory firm in global sourcing - provides a solid platform upon which to build a prominent, high-growth information-based services company. Based in Stamford, Connecticut, ISG has a proven leadership team with global experience in information-based services and a track record of creating significant value for shareowners, clients and employees. ISG's strategy is to acquire and grow dynamic, innovative businesses that provide `must have` information-based services to such sectors as consumer products, retailing, financial services, manufacturing, media, marketing, healthcare, legal, government, telecommunications and technology. Information Services Group Inc has a market cap of $110.9 million; its shares were traded at around $3.52 with a P/E ratio of 12.2 and P/S ratio of 0.6.
Buy:: Chairman and CEO, 10% Owner Michael P Connors bought 315,457 shares of III stock on 11/12/2009 at the average price of 3.17, the price of the stock has increased by 11.04% since. Sell:: 10% Owner Frank Martell sold 440,457 shares of III stock on 11/12/2009 at the average price of 3.17, the price of the stock has increased by 11.04% since. Sell:: 10% Owner Eric Semler sold 231,000 shares of III stock on 11/04/2009 at the average price of 3.47 and 94,900 shares of III stock on 11/05/2009 at the average price of 3.3, the price of the stock has increased by 6.67% since.
Magnum Hunter Resources Inc. (MHR): CFO and Exe. VP Ronald D Ormand Bought 57,800 Shares
CFO and Exe. VP of Magnum Hunter Resources Inc. (MHR) Ronald D Ormand bought 57,800 shares on 11/05/2009 at an average price of $1.73. Magnum Hunter Resources Corporation, formerly Petro Resources Corporation, is an independent oil and gas company engaged in the acquisition, drilling and production of oil and natural gas properties and prospects within the United States. The acquisition and exploration pursuits of oil and natural gas properties are located in Texas, Louisiana, North Dakota, New Mexico and Kentucky. The Company's drilling inventory includes prospects located in Texas, Louisiana, New Mexico, North Dakota and Kentucky. The company is based in Houston, Texas. Magnum Hunter Resources Inc. has a market cap of $66.6 million; its shares were traded at around $1.63 with and P/S ratio of 4.3.
Magnum Hunter Resources Inc. recently reported and financial results today for the third period 2009 ended September 30, 2009. Magnum Hunter reported a net loss of $3.1 million, or ($0.08) per basic and fully diluted shares outstanding for the third quarter of 2009, as compared to 2008's third quarter net loss of $535.5 thousand, or ($0.01) per basic and fully diluted shares outstanding.
Buy:: Director Jeff Swanson bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Exec VP Hershal C Iii Ferguson bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Director Gary L Hall bought 57,800 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Director Joe L Mcclaugherty bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Chairman of the Board Gary C Evans bought 86,705 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since.
Columbia Laboratories Inc. (CBRX): Senior Vice Prsident & CFO Lawrence A Gyenes Bought 50,000 Shares
Senior Vice Prsident & CFO of Columbia Laboratories Inc. (CBRX) Lawrence A Gyenes bought 50,000 shares on 11/09/2009 at an average price of $0.87. Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of reproductive healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE prand PROCHIEVE in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE for the treatment of secondary amenorrhea. The Company also markets STRIANT for the treatment of hypogonadism in men. The Company recently completed the treatment phase of its 669-patient pivotal Phase III study to evaluate the possible utility of PROCHIEVE for the prevention of recurrent preterm birth. The Company expects to announce efficacy and preliminary safety results from this randomized, double-blind, placebo-controlled clinical trial in mid-February. Columbia Laboratories Inc. has a market cap of $46.1 million; its shares were traded at around $0.842 with and P/S ratio of 1.3.
Columbia Laboratories, Inc. reported financial results for the three- and nine-month periods ended September 30, 2009. Net revenues were $7.9 million as compared to $11.1 million for the third quarter of 2008.
Buy:: Director Selwyn P Oskowitz bought 1,000 shares of CBRX stock on 11/10/2009 at the average price of 0.85 and 700 shares of CBRX stock on 11/13/2009 at the average price of 0.99, the price of the stock has decreased by 14.95% since. Buy:: Director Stephen G Kasnet bought 40,000 shares of CBRX stock on 11/09/2009 at the average price of 0.85 and 10,000 shares of CBRX stock on 11/11/2009 at the average price of 0.99, the price of the stock has decreased by 0.94% since.
NewBridge Bancorp (NBBC): EVP and CFO Ramsey K Hamadi Bought 14,100 Shares
EVP and CFO of NewBridge Bancorp (NBBC) Ramsey K Hamadi bought 14,100 shares on 11/05/2009 at an average price of $2.5. LSB Bancshares, Inc. is a bank holding company whose principal business is providing banking and other financial services through its banking subsidiary. LSB Bancshares is the parent holding company of Lexington State Bank. Newbridge Bancorp has a market cap of $35.5 million; its shares were traded at around $2.27 with and P/S ratio of 0.3.
NewBridge Bancorp recently reported financial results for the three and nine month periods ended September 30, 2009. For the three months ended September 30, 2009, net loss was $5.7 million and net loss available to common shareholders was $6.4 million, or $0.41 per diluted share, compared to net loss of $1.6 million, or $0.10 per diluted share, in the third quarter of 2008.
Buy:: Director Burr W Sullivan bought 4,000 shares of NBBC stock on 11/11/2009 at the average price of 2.3, the price of the stock has decreased by 1.3% since. Buy:: Director Robert Cunningham Clark bought 1,000 shares of NBBC stock on 11/10/2009 at the average price of 2.28, the price of the stock has decreased by 0.44% since. Buy:: Director Joseph H Kinnarney bought 2,200 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since. Buy:: Director Elizabeth S Ward bought 2,000 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since. Buy:: Director James David Branch bought 1,900 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since.
Oculus Innovative Sciences Inc. (OCLS): CFO Robert E Miller Bought 13,000 Shares
CFO of Oculus Innovative Sciences Inc. (OCLS) Robert E Miller bought 13,000 shares on 11/11/2009 at an average price of $1.68. OCULUS INNOVATIVE SCIENCES, INC. is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers. Oculus Innovative Sciences Inc. has a market cap of $38.6 million; its shares were traded at around $1.6301 with and P/S ratio of 7.2.
Oculus Innovative Sciences, Inc. announced financial and operating results for the second quarter of fiscal year 2010, ended September 30. The net loss for the fiscal 2010 second quarter was $1.9 million, or $0.08 per share, compared with the net loss for the fiscal 2009 second quarter of $6.9 million, or $0.43 per share. The company reported total revenue of $1.7 million in the second quarter of fiscal 2010, compared to $1.5 million in the second quarter of fiscal 2009.
Sell:: CEO Hojabr Alimi sold 315,000 shares of OCLS stock on 08/10/2009 at the average price of 2.09, the price of the stock has decreased by 22% since. Buy:: Vice President James J Schutz bought 5,000 shares of OCLS stock on 08/12/2009 at the average price of 2.04, the price of the stock has decreased by 20.09% since. Sell:: Director Richard K Conley sold 25,000 shares of OCLS stock on 09/10/2009 at the average price of 2.77, the price of the stock has decreased by 41.15% since.
Synovus Financial Corp. (SNV): EVP and CFO Thomas J Prescott Bought 10,000 Shares
EVP and CFO of Synovus Financial Corp. (SNV) Thomas J Prescott bought 10,000 shares on 11/05/2009 at an average price of $1.91. Synovus Financial Corp. is engaged in two reportable business segments: banking, which is primarily involved in commercial banking activities and also provides retail banking, trust services, mortgage banking, securities brokerage and insurance services, and transaction processing, which includes credit, debit, commercial and retail card processing and related services and debt collection and bankruptcy management services. Synovus Financial Corp. has a market cap of $927.1 million; its shares were traded at around $1.93 with and P/S ratio of 0.4. The dividend yield of Synovus Financial Corp. stocks is 2.1%. Synovus Financial Corp. had an annual average earning growth of 10.4% over the past 10 years. GuruFocus rated Synovus Financial Corp. the business predictability rank of 2.5-star.
Synovus Financial Corp. recently reported its results of operations for the third quarter of 2009. The net loss for the third quarter of 2009 was $423.7 million, or $1.27 per common share.
Buy:: Chairman of the Board and CEO Richard E Anthony bought 30,000 shares of SNV stock on 11/12/2009 at the average price of 1.85, the price of the stock has increased by 4.32% since. Buy:: Director James H Blanchard bought 15,000 shares of SNV stock on 09/22/2009 at the average price of 4 and 20,000 shares of SNV stock on 11/10/2009 at the average price of 1.98, the price of the stock has decreased by 2.53% since. Buy:: Director Frank W Brumley bought 25,000 shares of SNV stock on 11/06/2009 at the average price of 2.06, the price of the stock has decreased by 6.31% since. Buy:: Director Richard Y Bradley bought 10,000 shares of SNV stock on 10/28/2009 at the average price of 1.92, the price of the stock has increased by 0.52% since. Buy:: Director H Lynn Page bought 30,000 shares of SNV stock on 10/27/2009 at the average price of 2.55, the price of the stock has decreased by 24.31% since.
QLT Inc. (QLTI): VP, Finance and CFO Cameron Nelson Bought 10,000 Shares
VP, Finance and CFO of QLT Inc. (QLTI) Cameron Nelson bought 10,000 shares on 11/06/2009 at an average price of $3.58. QLT PhotoTherapeutics Inc. is a world leader in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy, an emerging field of medicine utilizing light-activated drugs in the treatment of disease. QLT's innovative science has advanced photodynamic therapy beyond applications in cancer towards potential breakthrough treatments in ophthalmology and autoimmune disease. (PRESS RELEASE) Qlt Inc. has a market cap of $208.7 million; its shares were traded at around $3.82 with a P/E ratio of 18.2 and P/S ratio of 1.6.
QLT Inc. recently reported financial results for the third quarter ended September 30, 2009. For the third quarter, revenue of $8.8 million was down 19.2% from the third quarter of 2008. EPS of $0.16 in the third quarter compared to EPS of $1.97 in the prior-year quarter.
QLTI is in the portfolios of Charles Brandes of Brandes Investment, Arnold Van Den Berg of Century Management.
Buy:: President and CEO Robert Butchofsky bought 10,000 shares of QLTI stock on 11/03/2009 at the average price of 3.4, the price of the stock has increased by 12.35% since. Buy:: Director C Boyd Clarke bought 5,000 shares of QLTI stock on 11/03/2009 at the average price of 3.39, the price of the stock has increased by 12.68% since. Sell:: 10% Owner Public Equity K/s Nb sold 2,000,000 shares of QLTI stock on 10/21/2009 at the average price of 3.2, the price of the stock has increased by 19.38% since. Sell:: 10% Owner Public Equity K/s Nb sold 263,801 shares of QLTI stock on 10/19/2009 at the average price of 3.97, the price of the stock has decreased by 3.78% since.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
Information Services Group Inc (III): Executive VP and CFO David E. Berger Bought 125,000 Shares
Executive VP and CFO of Information Services Group Inc (III) David E. Berger bought 125,000 shares on 11/12/2009 at an average price of $3.17. INFORMATION SERVICES GROUP, INC. was founded to build an industry-leading, high-growth, information-based services company by acquiring and growing businesses in advisory, data, business and media information services. ISG's first acquisition - TPI, the world's leading data and advisory firm in global sourcing - provides a solid platform upon which to build a prominent, high-growth information-based services company. Based in Stamford, Connecticut, ISG has a proven leadership team with global experience in information-based services and a track record of creating significant value for shareowners, clients and employees. ISG's strategy is to acquire and grow dynamic, innovative businesses that provide `must have` information-based services to such sectors as consumer products, retailing, financial services, manufacturing, media, marketing, healthcare, legal, government, telecommunications and technology. Information Services Group Inc has a market cap of $110.9 million; its shares were traded at around $3.52 with a P/E ratio of 12.2 and P/S ratio of 0.6.
Buy:: Chairman and CEO, 10% Owner Michael P Connors bought 315,457 shares of III stock on 11/12/2009 at the average price of 3.17, the price of the stock has increased by 11.04% since. Sell:: 10% Owner Frank Martell sold 440,457 shares of III stock on 11/12/2009 at the average price of 3.17, the price of the stock has increased by 11.04% since. Sell:: 10% Owner Eric Semler sold 231,000 shares of III stock on 11/04/2009 at the average price of 3.47 and 94,900 shares of III stock on 11/05/2009 at the average price of 3.3, the price of the stock has increased by 6.67% since.
Magnum Hunter Resources Inc. (MHR): CFO and Exe. VP Ronald D Ormand Bought 57,800 Shares
CFO and Exe. VP of Magnum Hunter Resources Inc. (MHR) Ronald D Ormand bought 57,800 shares on 11/05/2009 at an average price of $1.73. Magnum Hunter Resources Corporation, formerly Petro Resources Corporation, is an independent oil and gas company engaged in the acquisition, drilling and production of oil and natural gas properties and prospects within the United States. The acquisition and exploration pursuits of oil and natural gas properties are located in Texas, Louisiana, North Dakota, New Mexico and Kentucky. The Company's drilling inventory includes prospects located in Texas, Louisiana, New Mexico, North Dakota and Kentucky. The company is based in Houston, Texas. Magnum Hunter Resources Inc. has a market cap of $66.6 million; its shares were traded at around $1.63 with and P/S ratio of 4.3.
Magnum Hunter Resources Inc. recently reported and financial results today for the third period 2009 ended September 30, 2009. Magnum Hunter reported a net loss of $3.1 million, or ($0.08) per basic and fully diluted shares outstanding for the third quarter of 2009, as compared to 2008's third quarter net loss of $535.5 thousand, or ($0.01) per basic and fully diluted shares outstanding.
Buy:: Director Jeff Swanson bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Exec VP Hershal C Iii Ferguson bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Director Gary L Hall bought 57,800 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Director Joe L Mcclaugherty bought 14,450 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since. Buy:: Chairman of the Board Gary C Evans bought 86,705 shares of MHR stock on 11/05/2009 at the average price of 1.73, the price of the stock has decreased by 5.78% since.
Columbia Laboratories Inc. (CBRX): Senior Vice Prsident & CFO Lawrence A Gyenes Bought 50,000 Shares
Senior Vice Prsident & CFO of Columbia Laboratories Inc. (CBRX) Lawrence A Gyenes bought 50,000 shares on 11/09/2009 at an average price of $0.87. Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of reproductive healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE prand PROCHIEVE in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE for the treatment of secondary amenorrhea. The Company also markets STRIANT for the treatment of hypogonadism in men. The Company recently completed the treatment phase of its 669-patient pivotal Phase III study to evaluate the possible utility of PROCHIEVE for the prevention of recurrent preterm birth. The Company expects to announce efficacy and preliminary safety results from this randomized, double-blind, placebo-controlled clinical trial in mid-February. Columbia Laboratories Inc. has a market cap of $46.1 million; its shares were traded at around $0.842 with and P/S ratio of 1.3.
Columbia Laboratories, Inc. reported financial results for the three- and nine-month periods ended September 30, 2009. Net revenues were $7.9 million as compared to $11.1 million for the third quarter of 2008.
Buy:: Director Selwyn P Oskowitz bought 1,000 shares of CBRX stock on 11/10/2009 at the average price of 0.85 and 700 shares of CBRX stock on 11/13/2009 at the average price of 0.99, the price of the stock has decreased by 14.95% since. Buy:: Director Stephen G Kasnet bought 40,000 shares of CBRX stock on 11/09/2009 at the average price of 0.85 and 10,000 shares of CBRX stock on 11/11/2009 at the average price of 0.99, the price of the stock has decreased by 0.94% since.
NewBridge Bancorp (NBBC): EVP and CFO Ramsey K Hamadi Bought 14,100 Shares
EVP and CFO of NewBridge Bancorp (NBBC) Ramsey K Hamadi bought 14,100 shares on 11/05/2009 at an average price of $2.5. LSB Bancshares, Inc. is a bank holding company whose principal business is providing banking and other financial services through its banking subsidiary. LSB Bancshares is the parent holding company of Lexington State Bank. Newbridge Bancorp has a market cap of $35.5 million; its shares were traded at around $2.27 with and P/S ratio of 0.3.
NewBridge Bancorp recently reported financial results for the three and nine month periods ended September 30, 2009. For the three months ended September 30, 2009, net loss was $5.7 million and net loss available to common shareholders was $6.4 million, or $0.41 per diluted share, compared to net loss of $1.6 million, or $0.10 per diluted share, in the third quarter of 2008.
Buy:: Director Burr W Sullivan bought 4,000 shares of NBBC stock on 11/11/2009 at the average price of 2.3, the price of the stock has decreased by 1.3% since. Buy:: Director Robert Cunningham Clark bought 1,000 shares of NBBC stock on 11/10/2009 at the average price of 2.28, the price of the stock has decreased by 0.44% since. Buy:: Director Joseph H Kinnarney bought 2,200 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since. Buy:: Director Elizabeth S Ward bought 2,000 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since. Buy:: Director James David Branch bought 1,900 shares of NBBC stock on 10/30/2009 at the average price of 2.5, the price of the stock has decreased by 9.2% since.
Oculus Innovative Sciences Inc. (OCLS): CFO Robert E Miller Bought 13,000 Shares
CFO of Oculus Innovative Sciences Inc. (OCLS) Robert E Miller bought 13,000 shares on 11/11/2009 at an average price of $1.68. OCULUS INNOVATIVE SCIENCES, INC. is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers. Oculus Innovative Sciences Inc. has a market cap of $38.6 million; its shares were traded at around $1.6301 with and P/S ratio of 7.2.
Oculus Innovative Sciences, Inc. announced financial and operating results for the second quarter of fiscal year 2010, ended September 30. The net loss for the fiscal 2010 second quarter was $1.9 million, or $0.08 per share, compared with the net loss for the fiscal 2009 second quarter of $6.9 million, or $0.43 per share. The company reported total revenue of $1.7 million in the second quarter of fiscal 2010, compared to $1.5 million in the second quarter of fiscal 2009.
Sell:: CEO Hojabr Alimi sold 315,000 shares of OCLS stock on 08/10/2009 at the average price of 2.09, the price of the stock has decreased by 22% since. Buy:: Vice President James J Schutz bought 5,000 shares of OCLS stock on 08/12/2009 at the average price of 2.04, the price of the stock has decreased by 20.09% since. Sell:: Director Richard K Conley sold 25,000 shares of OCLS stock on 09/10/2009 at the average price of 2.77, the price of the stock has decreased by 41.15% since.
Synovus Financial Corp. (SNV): EVP and CFO Thomas J Prescott Bought 10,000 Shares
EVP and CFO of Synovus Financial Corp. (SNV) Thomas J Prescott bought 10,000 shares on 11/05/2009 at an average price of $1.91. Synovus Financial Corp. is engaged in two reportable business segments: banking, which is primarily involved in commercial banking activities and also provides retail banking, trust services, mortgage banking, securities brokerage and insurance services, and transaction processing, which includes credit, debit, commercial and retail card processing and related services and debt collection and bankruptcy management services. Synovus Financial Corp. has a market cap of $927.1 million; its shares were traded at around $1.93 with and P/S ratio of 0.4. The dividend yield of Synovus Financial Corp. stocks is 2.1%. Synovus Financial Corp. had an annual average earning growth of 10.4% over the past 10 years. GuruFocus rated Synovus Financial Corp. the business predictability rank of 2.5-star.
Synovus Financial Corp. recently reported its results of operations for the third quarter of 2009. The net loss for the third quarter of 2009 was $423.7 million, or $1.27 per common share.
Buy:: Chairman of the Board and CEO Richard E Anthony bought 30,000 shares of SNV stock on 11/12/2009 at the average price of 1.85, the price of the stock has increased by 4.32% since. Buy:: Director James H Blanchard bought 15,000 shares of SNV stock on 09/22/2009 at the average price of 4 and 20,000 shares of SNV stock on 11/10/2009 at the average price of 1.98, the price of the stock has decreased by 2.53% since. Buy:: Director Frank W Brumley bought 25,000 shares of SNV stock on 11/06/2009 at the average price of 2.06, the price of the stock has decreased by 6.31% since. Buy:: Director Richard Y Bradley bought 10,000 shares of SNV stock on 10/28/2009 at the average price of 1.92, the price of the stock has increased by 0.52% since. Buy:: Director H Lynn Page bought 30,000 shares of SNV stock on 10/27/2009 at the average price of 2.55, the price of the stock has decreased by 24.31% since.
QLT Inc. (QLTI): VP, Finance and CFO Cameron Nelson Bought 10,000 Shares
VP, Finance and CFO of QLT Inc. (QLTI) Cameron Nelson bought 10,000 shares on 11/06/2009 at an average price of $3.58. QLT PhotoTherapeutics Inc. is a world leader in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy, an emerging field of medicine utilizing light-activated drugs in the treatment of disease. QLT's innovative science has advanced photodynamic therapy beyond applications in cancer towards potential breakthrough treatments in ophthalmology and autoimmune disease. (PRESS RELEASE) Qlt Inc. has a market cap of $208.7 million; its shares were traded at around $3.82 with a P/E ratio of 18.2 and P/S ratio of 1.6.
QLT Inc. recently reported financial results for the third quarter ended September 30, 2009. For the third quarter, revenue of $8.8 million was down 19.2% from the third quarter of 2008. EPS of $0.16 in the third quarter compared to EPS of $1.97 in the prior-year quarter.
QLTI is in the portfolios of Charles Brandes of Brandes Investment, Arnold Van Den Berg of Century Management.
Buy:: President and CEO Robert Butchofsky bought 10,000 shares of QLTI stock on 11/03/2009 at the average price of 3.4, the price of the stock has increased by 12.35% since. Buy:: Director C Boyd Clarke bought 5,000 shares of QLTI stock on 11/03/2009 at the average price of 3.39, the price of the stock has increased by 12.68% since. Sell:: 10% Owner Public Equity K/s Nb sold 2,000,000 shares of QLTI stock on 10/21/2009 at the average price of 3.2, the price of the stock has increased by 19.38% since. Sell:: 10% Owner Public Equity K/s Nb sold 263,801 shares of QLTI stock on 10/19/2009 at the average price of 3.97, the price of the stock has decreased by 3.78% since.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
